|
1
|
Best LM, Mughal M and Gurusamy KS:
Laparoscopic versus open gastrectomy for gastric cancer. Cochrane
Database Syst Rev. 3:Cd0113892016.PubMed/NCBI
|
|
2
|
Correa P: Gastric cancer: Overview.
Gastroenterol Clin North Am. 42:211–217. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yang L: Incidence and mortality of gastric
cancer in China. World J Gastroenterol. 12:17–20. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee KS, Oh DK, Han MA, Lee HY, Jun JK,
Choi KS and Park EC: Gastric cancer screening in Korea: Report on
the national cancer screening program in 2008. Cancer Res Treat.
43:83–88. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hamashima C, Shibuya D, Yamazaki H, Inoue
K, Fukao A, Saito H and Sobue T: The Japanese guidelines for
gastric cancer screening. Jpn J Clin Oncol. 38:259–267. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jung KW, Park S, Kong HJ, Won YJ, Lee JY,
Seo HG and Lee JS: Cancer statistics in Korea: Incidence,
mortality, survival, and prevalence in 2009. Cancer Res Treat.
44:11–24. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nishikawa K, Iwase K, Aono T, Yoshida H,
Nomura M, Tamagawa H, Matsuda C, Deguchi T, Kawada J, Higashi S, et
al: Efficacy of capecitabine/cisplatin chemotherapy after failure
of all conventional therapies in patients with advanced gastric
cancer. Gan To Kagaku Ryoho. 40:57–60. 2013.(In Japanese).
PubMed/NCBI
|
|
9
|
Turaga KK, Gamblin TC and Pappas S:
Surgical treatment of peritoneal carcinomatosis from gastric
cancer. Int J Surg Oncol. 2012:4056522012.PubMed/NCBI
|
|
10
|
Bessette DC, Qiu D and Pallen CJ: PRL
PTPs: Mediators and markers of cancer progression. Cancer
Metastasis Rev. 27:231–252. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Slordahl TS, Abdollahi P, Vandsemb EN,
Rampa C, Misund K, Baranowska KA, Westhrin M, Waage A, Rø TB and
Børset M: The phosphatase of regenerating liver-3 (PRL-3) is
important for IL-6-mediated survival of myeloma cells. Oncotarget.
7:27295–27306. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Miskad UA, Semba S, Kato H and Yokozaki H:
Expression of PRL-3 phosphatase in human gastric carcinomas: Close
correlation with invasion and metastasis. Pathobiology. 71:176–184.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li ZR, Wang Z, Zhu BH, He YL, Peng JS, Cai
SR, Ma JP and Zhan WH: Association of tyrosine PRL-3 phosphatase
protein expression with peritoneal metastasis of gastric carcinoma
and prognosis. Surg Today. 37:646–651. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dong Q, Ding X, Chang B, Wang H and Wang
A: PRL-3 promotes migration and invasion and is associated with
poor prognosis in salivary adenoid cystic carcinoma. J Oral Pathol
Med. 45:111–118. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kato H, Semba S, Miskad UA, Seo Y, Kasuga
M and Yokozaki H: High expression of PRL-3 promotes cancer cell
motility and liver metastasis in human colorectal cancer: A
predictive molecular marker of metachronous liver and lung
metastases. Clin Cancer Res. 10:7318–7328. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dai N, Lu AP, Shou CC and Li JY:
Expression of phosphatase regenerating liver 3 is an independent
prognostic indicator for gastric cancer. World J Gastroenterol.
15:1499–1505. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fruman DA and Rommel C: PI3K and cancer:
Lessons, challenges and opportunities. Nat Rev Drug Discov.
13:140–156. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vara Fresno JA, Casado E, de Castro J,
Cejas P, Belda-Iniesta C and Gonzalez-Baron M: PI3K/Akt signalling
pathway and cancer. Cancer Treat Rev. 30:193–204. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tapia O, Riquelme I, Leal P, Sandoval A,
Aedo S, Weber H, Letelier P, Bellolio E, Villaseca M, Garcia P and
Roa JC: The PI3K/AKT/mTOR pathway is activated in gastric cancer
with potential prognostic and predictive significance. Virchows
Arch. 465:25–33. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang H, Quah SY, Dong JM, Manser E, Tang
JP and Zeng Q: PRL-3 down-regulates PTEN expression and signals
through PI3K to promote epithelial-mesenchymal transition. Cancer
Res. 67:2922–2926. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xiong J, Li Z, Zhang Y, Li D, Zhang G, Luo
X, Jie Z, Liu Y, Cao Y, Le Z, et al: PRL-3 promotes the peritoneal
metastasis of gastric cancer through the PI3K/Akt signaling pathway
by regulating PTEN. Oncol Rep. 36:1819–1828. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Vlahos CJ, Matter WF, Hui KY and Brown RF:
A specific inhibitor of phosphatidylinositol 3-kinase,
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol
Chem. 269:5241–5248. 1994.PubMed/NCBI
|
|
23
|
Liu Y, Zheng P, Liu Y, Ji T, Liu X, Yao S,
Cheng X, Li Y, Chen L, Xiao Z, et al: An epigenetic role for PRL-3
as a regulator of H3K9 methylation in colorectal cancer. Gut.
62:571–581. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mollevi DG, Aytes A, Padulles L,
Martínez-Iniesta M, Baixeras N, Salazar R, Ramos E, Figueras J,
Capella G, Villanueva A, et al: PRL-3 is essentially overexpressed
in primary colorectal tumours and associates with tumour
aggressiveness. Br J Cancer. 99:1718–1725. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mayinuer A, Yasen M, Mogushi K, Obulhasim
G, Xieraili M, Aihara A, Tanaka S, Mizushima H, Tanaka H and Arii
S: Upregulation of protein tyrosine phosphatase type IVA member 3
(PTP4A3/PRL-3) is associated with tumor differentiation and a poor
prognosis in human hepatocellular carcinoma. Ann Surg Oncol.
20:305–317. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Khapare N, Kundu ST, Sehgal L, Sawant M,
Priya R, Gosavi P, Gupta N, Alam H, Karkhanis M, Naik N, et al:
Plakophilin3 loss leads to an increase in PRL3 levels promoting K8
dephosphorylation, which is required for transformation and
metastasis. PLoS One. 7:e385612012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jiang H, Fan D, Zhou G, Li X and Deng H:
Phosphatidylinositol 3-kinase inhibitor (LY294002) induces
apoptosis of human nasopharyngeal carcinoma in vitro and in vivo. J
Exp Clin Cancer Res. 29:342010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Luo Y, Liang F and Zhang ZY: PRL1 promotes
cell migration and invasion by increasing MMP2 and MMP9 expression
through Src and ERK1/2 pathways. Biochemistry. 48:1838–1846. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Matsuoka T, Yashiro M, Nishioka N,
Hirakawa K, Olden K and Roberts JD: PI3K/Akt signalling is required
for the attachment and spreading, and growth in vivo of metastatic
scirrhous gastric carcinoma. Br J Cancer. 106:1535–1542. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sun L, Liu L, Liu X, Wang Y, Li M, Yao L,
Yang J, Ji G, Guo C, Pan Y, et al: MGr1-Ag/37LRP induces cell
adhesion-mediated drug resistance through FAK/PI3K and MAPK pathway
in gastric cancer. Cancer Sci. 105:651–659. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Almhanna K, Strosberg J and Malafa M:
Targeting AKT protein kinase in gastric cancer. Anticancer Res.
31:4387–4392. 2011.PubMed/NCBI
|
|
32
|
Jia Y, Sun H, Wu H, Zhang H, Zhang X, Xiao
D, Ma X and Wang Y: Nicotine Inhibits Cisplatin-Induced Apoptosis
via regulating α5-nAChR/AKT signaling in human gastric cancer
cells. PLoS One. 11:e01491202016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Semba S, Itoh N, Ito M, Harada M and
Yamakawa M: The in vitro and in vivo effects of
2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific
inhibitor of phosphatidylinositol 3′-kinase, in human colon cancer
cells. Clin Cancer Res. 8:1957–1963. 2002.PubMed/NCBI
|
|
34
|
Hu L, Zaloudek C, Mills GB, Gray J and
Jaffe RB: In vivo and in vitro ovarian carcinoma growth inhibition
by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin
Cancer Res. 6:880–886. 2000.PubMed/NCBI
|
|
35
|
Zhao K, Zhu BS, Gong W, Zhu ML, Gao ZT, Wu
YY, Chen Q, Yang XD and Xing CG: SN50 enhances the effects of
LY294002 on cell death induction in gastric cancer cell line
SGC7901. Arch Med Sci. 9:990–998. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Polacheck WJ, Zervantonakis IK and Kamm
RD: Tumor cell migration in complex microenvironments. Cell Mol
Life Sci. 70:1335–1356. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Folkman J: Tumor angiogenesis: Therapeutic
implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Egeblad M and Werb Z: New functions for
the matrix metalloproteinases in cancer progression. Nat Rev
Cancer. 2:161–174. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
39
|
Foda HD and Zucker S: Matrix
metalloproteinases in cancer invasion, metastasis and angiogenesis.
Drug Discov Today. 6:478–482. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Furuya F, Hanover JA and Cheng SY:
Activation of phosphatidylinositol 3-kinase signaling by a mutant
thyroid hormone beta receptor. Proc Natl Acad Sci USA.
103:1780–1785. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kang MH, Oh SC, Lee HJ, Kang HN, Kim JL,
Kim JS and Yoo YA: Metastatic function of BMP-2 in gastric cancer
cells: the role of PI3K/AKT, MAPK, the NF-κB pathway, and MMP-9
expression. Exp Cell Res. 317:1746–1762. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chien CS, Shen KH, Huang JS, Ko SC and
Shih YW: Antimetastatic potential of fisetin involves inactivation
of the PI3K/Akt and JNK signaling pathways with downregulation of
MMP-2/9 expressions in prostate cancer PC-3 cells. Mol Cell
Biochem. 333:169–180. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Xu JEC, Yao Y, Ren S, Wang G and Jin H:
Matrix metalloproteinase expression and molecular interaction
network analysis in gastric cancer. Oncol Lett. 12:2403–2408. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Brannon-Peppas L and Blanchette JO:
Nanoparticle and targeted systems for cancer therapy. Adv Drug
Deliv Rev. 64:206–212. 2012. View Article : Google Scholar
|
